Funding information:
Not applicable
References:
  1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing X. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine. 2020 Jan 29.
  2. Li J, You Z, Wang Q, Zhou Z, Qiu Y, Luo R et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes and Infection. 2020;22(2):80-85.
  3. Sharma A, Tiwari S, Deb MK, MARTY JL. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A global pandemic and treatments strategies. International Journal of Antimicrobial Agents. 2020 Jun 10:106054.
  4. Coronavirus Update (Live): 13,039,853 Cases and 571,659 Deaths from COVID-19 Virus Pandemic - Worldometer [Internet]. Worldometers.info. 2020 [cited 13 July 2020]. Available from: https://www.worldometers.info/coronavirus/
  5. Romagnoli S, Peris A, De Gaudio AR, Geppetti P. SARS-CoV-2 and COVID-19: between pathophysiology complexity and therapeutic uncertainty. Physiological reviews. 2020 Jun 4.
  6. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases. 2020 Apr 1;20(4):398-400.
  7. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther [Internet]. 2020; 14 (1): 58–60.
  8. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care. 2020 Mar 10.
  9. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases. 2020 Apr 1;20(4):400-2.
  10. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020 May 19;117(20):10970-5.
  11. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research. 2020 Apr 3:104787.
  12. Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Del Pozo CH, Prosper F, Romero JP. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020 Apr 24.
  13. Gurwitz D. Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics. Drug development research. 2020 Mar 4.
  14. Chen YW, Yiu CP, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research. 2020;9.
  15. Wang C, Li W, Drabek D, Okba NM, van Haperen R, Osterhaus AD, van Kuppeveld FJ, Haagmans BL, Grosveld F, Bosch BJ. A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications. 2020 May 4;11(1):1-6.
  16. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery. 2020 Mar 18;6(1):1-4.
  17. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020 Apr 28;323(16):1582-9.
  18. Moore N. Chloroquine for COVID-19 Infection. Drug Saf  43,  393–394 (2020). https://doi.org/10.1007/s40264-020-00933-4
  19. Rismanbaf A. Potential treatments for COVID-19; a narrative literature review. Archives of Academic Emergency Medicine. 2020;8(1).
  20. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Jama. 2020 May 12;323(18):1824-36.
  21. ŞİMŞEK YAVUZ S, ÜNAL S. Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences. 2020 Apr 2;50.
  22. Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020 Mar 20:105949.
  23. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends. 2020.
  24. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. The Journal of clinical investigation. 2020 Apr 1;130(4):1545-8.
  25. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research. 2020 Dec;7(1):1-0.
  26. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical Infectious Diseases. 2020 Jan 1.
  27. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. 2020 Mar 9.
  28. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virologica Sinica. 2020 Mar 3:1-6.
  29. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal. 2005 Dec 1;2(1):69.
  30. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020 Apr 24;368(6489):409-12
  31. Zhang H, Penninger JM, Li Y , Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive care medicine. 2020 Apr;46(4):586-90.
  32. Nguyen TM, Zhang Y , Pandolfi PP . Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses.
  33. Bouadma L, Lescure FX, Lucet JC, Yazdanpanah Y , Timsit JF . Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists. Intensive care medicine. 2020 Apr;46(4):579-82.
  34. Poe FL, Corn J. N-Acetylcysteine: a potential therapeutic agent for SARS-CoV-2. Medical Hypotheses. 2020 May 30:109862.
  35. BIMONTE S, CRISPO A, AMORE A, CELENTANO E, CUOMO A, CASCELLA M. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. In Vivo. 2020 Jun 1;34(3 suppl):1597-602.
  36. ANDREOU A, TRANTZA S, FILIPPOU D, SIPSAS N, TSIODRAS S. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. In Vivo. 2020 Jun 1;34(3 suppl):1567-88.
  37. Lopes RD, Macedo AV, Moll-Bernardes RJ, Feldman A, Arruda GD, de Souza AS, de Albuquerque DC, Mazza L, Santos MF , Salvador NZ, Gibson CM. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). American Heart Journal. 2020 May 13.
  38. Ayaz S, Crea F . Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.
  39. Shu T, Huang M, Di Wu YR, Zhang X, Han Y , Mu J, Wang R, Qiu Y , Zhang DY , Zhou X. SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts. Virologica Sinica. 2020 Jun 4:1.
  40. Palanques-Pastor T, López-Briz E, Andrés JL. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19. European Journal of Hospital Pharmacy. 2020 Jun 4.
  41. Pandey A, Nikam AN, Shreya AB, Mutalik SP , Gopalan D, Kulkarni S, Padya BS, Fernandes G, Mutalik S, Prassl R. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Life Sciences. 2020 Jun 1:117883.
  42. Ibáñez S, Martínez O, Valenzuela F , Silva F , Valenzuela O. Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?. Clinical Rheumatology. 2020 Jun 3:1.
  43. Rilinger J, Kern WV, Duerschmied D, Supady A, Bode C, Staudacher DL, Wengenmayer T. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Dec;21(1):1-3.
  44. Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, Prajapat M, Shekhar N, Kumar S, Singh R, Singh A. Virological and clinical cure in COVID‐19 patients treated with hydroxychloroquine: a systematic review and meta‐analysis. Journal of medical virology. 2020 Apr 16.
  45. de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y , Thiel V, Narayanan K, Makino S, Snijder EJ, van Hemert MJ. Cyclosporin A inhibits the replication of diverse coronaviruses. The Journal of general virology. 2011 Nov;92(Pt 11):2542.
  46. Abeygunasekera A, Jayasinghe S. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?. Medical Hypotheses. 2020 May 18:109843.
  47. Biembengut ÍV, de Souza TD. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach. Memórias do Instituto Oswaldo Cruz. 2020;115.
  48. Irvani SS, Golmohammadi M, Pourhoseingholi MA, Shokouhi S, Darazam IA. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Dec;21(1):1-3.
  49. Tan EL, Ooi EE, Lin CY , Tan HC, Ling AE, Lim B, Stanton LW. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging infectious diseases. 2004 Apr; 10(4):581.
  50. Chu CM, Cheng VC, Hung IF , Wong MM, Chan KH, Chan KS, Kao RY , Poon LL, Wong CL, Guan Y , Peiris JS. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004 Mar 1;59(3):252-6.
  51. Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B, Ganesan S, Venugopal A, Venkatesan D, Ganesan H, Rajagopalan K. COVID-19: A promising cure for the global panic. Science of The Total Environment. 2020 Apr 4:138277.
  52. Zhang W, Zhao Y , Zhang F , Wang Q, Li T, Liu Z, Wang J, Qin Y , Zhang X, Yan X, Zeng X. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clinical Immunology. 2020 Mar 25:108393.
  53. Della-Torre E, Della-Torre F , Marija Kusanovic PC, Scotti R, Alvise-Ramirez G, Dagna L, Tresoldi M. Treating COVID-19 with colchicine in community healthcare setting. Clinical Immunology (Orlando, Fla.). 2020 May 31.
  54. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P , Kirkwood J, Muse A, DeHovitz J, Blog DS. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. Jama. 2020 May 11.
  55. Ye M, Fu D, Ren Y , Wang F , Wang D, Zhang F , Xia X, Lv T. Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China. Journal of Medical Virology. 2020 Apr 15.
  56. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. Journal of Infection. 2020 Apr 10.